#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The Flavivirus genus of the family Flaviviridae includes several arthropod-borne human pathogens that may cause a spectrum of clinical syndromes ranging from a mild febrile illness to severe hemorrhagic fever or neuroinvasive disease .
2-1	16-19	The	abstract[3]	new[3]	_	_
2-2	20-30	Flavivirus	plant|abstract[3]	new|new[3]	coref	17-20
2-3	31-36	genus	abstract[3]	new[3]	_	_
2-4	37-39	of	abstract[3]	new[3]	_	_
2-5	40-43	the	abstract[3]|person[4]|abstract[5]	new[3]|new[4]|new[5]	_	_
2-6	44-50	family	abstract[3]|person[4]|abstract[5]	new[3]|new[4]|new[5]	_	_
2-7	51-63	Flaviviridae	abstract[3]|abstract[5]	new[3]|new[5]	_	_
2-8	64-72	includes	_	_	_	_
2-9	73-80	several	substance[6]	new[6]	_	_
2-10	81-96	arthropod-borne	substance[6]	new[6]	_	_
2-11	97-102	human	substance[6]	new[6]	_	_
2-12	103-112	pathogens	substance[6]	new[6]	_	_
2-13	113-117	that	substance[6]	new[6]	_	_
2-14	118-121	may	substance[6]	new[6]	_	_
2-15	122-127	cause	substance[6]	new[6]	_	_
2-16	128-129	a	substance[6]|abstract[7]	new[6]|new[7]	_	_
2-17	130-138	spectrum	substance[6]|abstract[7]	new[6]|new[7]	_	_
2-18	139-141	of	substance[6]|abstract[7]	new[6]|new[7]	_	_
2-19	142-150	clinical	substance[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	coref	12-16[103_8]
2-20	151-160	syndromes	substance[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
2-21	161-168	ranging	substance[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
2-22	169-173	from	substance[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
2-23	174-175	a	substance[6]|abstract[7]|abstract[8]|event[9]	new[6]|new[7]|new[8]|new[9]	coref	4-9[38_9]
2-24	176-180	mild	substance[6]|abstract[7]|abstract[8]|event[9]	new[6]|new[7]|new[8]|new[9]	_	_
2-25	181-188	febrile	substance[6]|abstract[7]|abstract[8]|event[9]	new[6]|new[7]|new[8]|new[9]	_	_
2-26	189-196	illness	substance[6]|abstract[7]|abstract[8]|event[9]	new[6]|new[7]|new[8]|new[9]	_	_
2-27	197-199	to	substance[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
2-28	200-206	severe	substance[6]|abstract[7]|abstract[8]|abstract[10]	new[6]|new[7]|new[8]|new[10]	coref	11-33[94_10]
2-29	207-218	hemorrhagic	substance[6]|abstract[7]|abstract[8]|abstract[10]	new[6]|new[7]|new[8]|new[10]	_	_
2-30	219-224	fever	substance[6]|abstract[7]|abstract[8]|abstract[10]	new[6]|new[7]|new[8]|new[10]	_	_
2-31	225-227	or	substance[6]|abstract[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
2-32	228-241	neuroinvasive	substance[6]|abstract[7]|abstract[8]|abstract[11]	new[6]|new[7]|new[8]|new[11]	coref	4-13[39_11]
2-33	242-249	disease	substance[6]|abstract[7]|abstract[8]|abstract[11]	new[6]|new[7]|new[8]|new[11]	_	_
2-34	250-251	.	_	_	_	_

#Text=Neurotropic flaviviruses , such as West Nile virus ( WNV ) , Japanese encephalitis virus ( JEV ) , and tick-borne encephalitis virus ( TBEV ) , are maintained in nature in transmission cycles involving mosquito ( mainly Culex spp. ) or tick ( mainly Ixodes spp. ) vectors and mammalian or bird amplification hosts , with humans serving as dead-end incidental hosts .
3-1	252-263	Neurotropic	plant[12]	new[12]	coref	6-2[51_12]
3-2	264-276	flaviviruses	plant[12]	new[12]	_	_
3-3	277-278	,	plant[12]	new[12]	_	_
3-4	279-283	such	plant[12]	new[12]	_	_
3-5	284-286	as	plant[12]	new[12]	_	_
3-6	287-291	West	plant[12]|place[13]|abstract[14]	new[12]|new[13]|new[14]	appos	3-10[0_14]
3-7	292-296	Nile	plant[12]|place[13]|abstract[14]	new[12]|new[13]|new[14]	_	_
3-8	297-302	virus	plant[12]|abstract[14]	new[12]|new[14]	_	_
3-9	303-304	(	_	_	_	_
3-10	305-308	WNV	abstract	giv	coref	22-38
3-11	309-310	)	_	_	_	_
3-12	311-312	,	_	_	_	_
3-13	313-321	Japanese	abstract[17]	new[17]	appos	3-17[0_17]
3-14	322-334	encephalitis	abstract|abstract[17]	new|new[17]	coref	3-22
3-15	335-340	virus	abstract[17]	new[17]	_	_
3-16	341-342	(	_	_	_	_
3-17	343-346	JEV	abstract	giv	_	_
3-18	347-348	)	_	_	_	_
3-19	349-350	,	_	_	_	_
3-20	351-354	and	_	_	_	_
3-21	355-365	tick-borne	place|abstract[21]	new|new[21]	appos	3-25[0_21]
3-22	366-378	encephalitis	abstract|abstract[21]	giv|new[21]	_	_
3-23	379-384	virus	abstract[21]	new[21]	_	_
3-24	385-386	(	_	_	_	_
3-25	387-391	TBEV	abstract	giv	coref	5-1[44_0]
3-26	392-393	)	_	_	_	_
3-27	394-395	,	_	_	_	_
3-28	396-399	are	_	_	_	_
3-29	400-410	maintained	_	_	_	_
3-30	411-413	in	_	_	_	_
3-31	414-420	nature	abstract	new	_	_
3-32	421-423	in	_	_	_	_
3-33	424-436	transmission	abstract|event[25]	new|new[25]	_	_
3-34	437-443	cycles	event[25]	new[25]	_	_
3-35	444-453	involving	event[25]	new[25]	_	_
3-36	454-462	mosquito	event[25]|animal|person[32]	new[25]|new|new[32]	_	_
3-37	463-464	(	event[25]|person[32]	new[25]|new[32]	_	_
3-38	465-471	mainly	event[25]|time[28]|person[32]	new[25]|new[28]|new[32]	appos	3-45[31_28]
3-39	472-477	Culex	event[25]|plant|time[28]|person[32]	new[25]|new|new[28]|new[32]	_	_
3-40	478-482	spp.	event[25]|time[28]|person[32]	new[25]|new[28]|new[32]	_	_
3-41	483-484	)	event[25]|person[32]	new[25]|new[32]	_	_
3-42	485-487	or	event[25]|person[32]	new[25]|new[32]	_	_
3-43	488-492	tick	event[25]|animal|person[32]	new[25]|new|new[32]	_	_
3-44	493-494	(	event[25]|person[32]	new[25]|new[32]	_	_
3-45	495-501	mainly	event[25]|time[31]|person[32]	new[25]|giv[31]|new[32]	_	_
3-46	502-508	Ixodes	event[25]|animal|time[31]|person[32]	new[25]|new|giv[31]|new[32]	_	_
3-47	509-513	spp.	event[25]|time[31]|person[32]	new[25]|giv[31]|new[32]	_	_
3-48	514-515	)	event[25]|person[32]	new[25]|new[32]	_	_
3-49	516-523	vectors	event[25]|person[32]	new[25]|new[32]	_	_
3-50	524-527	and	_	_	_	_
3-51	528-537	mammalian	animal[34]	new[34]	coref	3-61[36_34]
3-52	538-540	or	animal[34]	new[34]	_	_
3-53	541-545	bird	animal[34]	new[34]	_	_
3-54	546-559	amplification	person|animal[34]	new|new[34]	_	_
3-55	560-565	hosts	animal[34]	new[34]	_	_
3-56	566-567	,	_	_	_	_
3-57	568-572	with	_	_	_	_
3-58	573-579	humans	animal	new	coref	9-5
3-59	580-587	serving	_	_	_	_
3-60	588-590	as	_	_	_	_
3-61	591-599	dead-end	animal[36]	giv[36]	coref	9-24[81_36]
3-62	600-610	incidental	animal[36]	giv[36]	_	_
3-63	611-616	hosts	animal[36]	giv[36]	_	_
3-64	617-618	.	_	_	_	_

#Text=Most human infections are asymptomatic or characterized by flu-like illness , while a severe and potentially fatal neuroinvasive disease occurs in a minority of cases , mostly immunocompromised and elderly individuals .
4-1	619-623	Most	abstract[37]	new[37]	coref	6-8[53_37]
4-2	624-629	human	abstract[37]	new[37]	_	_
4-3	630-640	infections	abstract[37]	new[37]	_	_
4-4	641-644	are	_	_	_	_
4-5	645-657	asymptomatic	_	_	_	_
4-6	658-660	or	_	_	_	_
4-7	661-674	characterized	_	_	_	_
4-8	675-677	by	_	_	_	_
4-9	678-686	flu-like	event[38]	giv[38]	coref	6-11[55_38]
4-10	687-694	illness	event[38]	giv[38]	_	_
4-11	695-696	,	_	_	_	_
4-12	697-702	while	_	_	_	_
4-13	703-704	a	abstract[39]	giv[39]	coref	11-45[97_39]
4-14	705-711	severe	abstract[39]	giv[39]	_	_
4-15	712-715	and	abstract[39]	giv[39]	_	_
4-16	716-727	potentially	abstract[39]	giv[39]	_	_
4-17	728-733	fatal	abstract[39]	giv[39]	_	_
4-18	734-747	neuroinvasive	abstract[39]	giv[39]	_	_
4-19	748-755	disease	abstract[39]	giv[39]	_	_
4-20	756-762	occurs	_	_	_	_
4-21	763-765	in	_	_	_	_
4-22	766-767	a	person[40]	new[40]	_	_
4-23	768-776	minority	person[40]	new[40]	_	_
4-24	777-779	of	person[40]	new[40]	_	_
4-25	780-785	cases	person[40]|event	new[40]|new	_	_
4-26	786-787	,	person[40]	new[40]	_	_
4-27	788-794	mostly	person[40]|person[42]	new[40]|new[42]	coref	8-14[71_42]
4-28	795-812	immunocompromised	person[40]|person[42]	new[40]|new[42]	_	_
4-29	813-816	and	person[40]|person[42]	new[40]|new[42]	_	_
4-30	817-824	elderly	person[40]|person[42]	new[40]|new[42]	_	_
4-31	825-836	individuals	person[40]|person[42]	new[40]|new[42]	_	_
4-32	837-838	.	_	_	_	_

#Text=Zika virus ( ZIKV ) has recently drawn attention due to the large outbreaks that occurred in Pacific Ocean countries and the Americas .
5-1	839-843	Zika	abstract|abstract[44]	new|giv[44]	appos|coref	5-4[0_44]|7-22
5-2	844-849	virus	abstract[44]	giv[44]	_	_
5-3	850-851	(	_	_	_	_
5-4	852-856	ZIKV	abstract	giv	coref	6-5
5-5	857-858	)	_	_	_	_
5-6	859-862	has	_	_	_	_
5-7	863-871	recently	_	_	_	_
5-8	872-877	drawn	_	_	_	_
5-9	878-887	attention	abstract	new	_	_
5-10	888-891	due	_	_	_	_
5-11	892-894	to	_	_	_	_
5-12	895-898	the	event[47]	new[47]	_	_
5-13	899-904	large	event[47]	new[47]	_	_
5-14	905-914	outbreaks	event[47]	new[47]	_	_
5-15	915-919	that	event[47]	new[47]	_	_
5-16	920-928	occurred	event[47]	new[47]	_	_
5-17	929-931	in	event[47]	new[47]	_	_
5-18	932-939	Pacific	event[47]|place[48]|place[49]	new[47]|new[48]|new[49]	_	_
5-19	940-945	Ocean	event[47]|place[48]|place[49]	new[47]|new[48]|new[49]	_	_
5-20	946-955	countries	event[47]|place[49]	new[47]|new[49]	_	_
5-21	956-959	and	event[47]	new[47]	_	_
5-22	960-963	the	event[47]|place[50]	new[47]|new[50]	_	_
5-23	964-972	Americas	event[47]|place[50]	new[47]|new[50]	_	_
5-24	973-974	.	_	_	_	_

#Text=Like other flaviviruses , ZIKV generally causes asymptomatic infections or a mild febrile illness .
6-1	975-979	Like	_	_	_	_
6-2	980-985	other	plant[51]	giv[51]	coref	10-3[0_51]
6-3	986-998	flaviviruses	plant[51]	giv[51]	_	_
6-4	999-1000	,	_	_	_	_
6-5	1001-1005	ZIKV	abstract	giv	coref	7-22[62_0]
6-6	1006-1015	generally	_	_	_	_
6-7	1016-1022	causes	_	_	_	_
6-8	1023-1035	asymptomatic	abstract[53]|abstract[54]	giv[53]|giv[54]	coref|coref	6-8[54_53]|12-21[104_54]
6-9	1036-1046	infections	abstract[53]|abstract[54]	giv[53]|giv[54]	_	_
6-10	1047-1049	or	abstract[54]	giv[54]	_	_
6-11	1050-1051	a	abstract[54]|event[55]	giv[54]|giv[55]	_	_
6-12	1052-1056	mild	abstract[54]|event[55]	giv[54]|giv[55]	_	_
6-13	1057-1064	febrile	abstract[54]|event[55]	giv[54]|giv[55]	_	_
6-14	1065-1072	illness	abstract[54]|event[55]	giv[54]|giv[55]	_	_
6-15	1073-1074	.	_	_	_	_

#Text=Infection during pregnancy , especially during the first trimester , causes fetal microcephaly and other developmental anomalies , defined as congenital Zika virus syndrome .
7-1	1075-1084	Infection	abstract[56]	new[56]	_	_
7-2	1085-1091	during	abstract[56]	new[56]	_	_
7-3	1092-1101	pregnancy	abstract[56]|event	new[56]|new	_	_
7-4	1102-1103	,	abstract[56]	new[56]	_	_
7-5	1104-1114	especially	abstract[56]|event[58]	new[56]|new[58]	_	_
7-6	1115-1121	during	abstract[56]|event[58]	new[56]|new[58]	_	_
7-7	1122-1125	the	abstract[56]|event[58]	new[56]|new[58]	_	_
7-8	1126-1131	first	abstract[56]|event[58]	new[56]|new[58]	_	_
7-9	1132-1141	trimester	abstract[56]|event[58]	new[56]|new[58]	_	_
7-10	1142-1143	,	_	_	_	_
7-11	1144-1150	causes	_	_	_	_
7-12	1151-1156	fetal	object[59]	new[59]	coref	18-42[192_59]
7-13	1157-1169	microcephaly	object[59]	new[59]	_	_
7-14	1170-1173	and	_	_	_	_
7-15	1174-1179	other	abstract[60]	new[60]	_	_
7-16	1180-1193	developmental	abstract[60]	new[60]	_	_
7-17	1194-1203	anomalies	abstract[60]	new[60]	_	_
7-18	1204-1205	,	abstract[60]	new[60]	_	_
7-19	1206-1213	defined	abstract[60]	new[60]	_	_
7-20	1214-1216	as	abstract[60]	new[60]	_	_
7-21	1217-1227	congenital	abstract[60]|abstract[63]	new[60]|new[63]	coref	8-1[66_63]
7-22	1228-1232	Zika	abstract[60]|abstract|abstract[62]|abstract[63]	new[60]|giv|giv[62]|new[63]	coref	8-11[0_62]
7-23	1233-1238	virus	abstract[60]|abstract[62]|abstract[63]	new[60]|giv[62]|new[63]	_	_
7-24	1239-1247	syndrome	abstract[60]|abstract[63]	new[60]|new[63]	_	_
7-25	1248-1249	.	_	_	_	_

#Text=Guillain – Barré syndrome and meningoencephalitis are rare complications of ZIKV infection in adult individuals .
8-1	1250-1258	Guillain	person|abstract[66]	new|giv[66]	_	_
8-2	1259-1260	–	abstract[66]	giv[66]	_	_
8-3	1261-1266	Barré	person|abstract[66]	new|giv[66]	_	_
8-4	1267-1275	syndrome	abstract[66]	giv[66]	_	_
8-5	1276-1279	and	_	_	_	_
8-6	1280-1299	meningoencephalitis	abstract	new	coref	8-8[68_0]
8-7	1300-1303	are	_	_	_	_
8-8	1304-1308	rare	abstract[68]	giv[68]	coref	11-19[89_68]
8-9	1309-1322	complications	abstract[68]	giv[68]	_	_
8-10	1323-1325	of	abstract[68]	giv[68]	_	_
8-11	1326-1330	ZIKV	abstract[68]|abstract|event[70]	giv[68]|giv|new[70]	coref|coref	9-1|12-32[0_70]
8-12	1331-1340	infection	abstract[68]|event[70]	giv[68]|new[70]	_	_
8-13	1341-1343	in	abstract[68]	giv[68]	_	_
8-14	1344-1349	adult	abstract[68]|person[71]	giv[68]|giv[71]	_	_
8-15	1350-1361	individuals	abstract[68]|person[71]	giv[68]|giv[71]	_	_
8-16	1362-1363	.	_	_	_	_

#Text=ZIKV is transmitted between humans through the bite of infected Ae . aegypti and other Aedes species mosquitoes , with humans serving as amplifying hosts .
9-1	1364-1368	ZIKV	abstract	giv	coref	10-5
9-2	1369-1371	is	_	_	_	_
9-3	1372-1383	transmitted	_	_	_	_
9-4	1384-1391	between	_	_	_	_
9-5	1392-1398	humans	animal	giv	coref	9-21
9-6	1399-1406	through	_	_	_	_
9-7	1407-1410	the	event[74]	new[74]	_	_
9-8	1411-1415	bite	event[74]	new[74]	_	_
9-9	1416-1418	of	event[74]	new[74]	_	_
9-10	1419-1427	infected	event[74]|animal[75]	new[74]|new[75]	appos	9-13[0_75]
9-11	1428-1430	Ae	event[74]|animal[75]	new[74]|new[75]	_	_
9-12	1431-1432	.	_	_	_	_
9-13	1433-1440	aegypti	animal	giv	_	_
9-14	1441-1444	and	_	_	_	_
9-15	1445-1450	other	animal[79]	new[79]	_	_
9-16	1451-1456	Aedes	animal|animal[78]|animal[79]	new|new[78]|new[79]	_	_
9-17	1457-1464	species	animal[78]|animal[79]	new[78]|new[79]	_	_
9-18	1465-1475	mosquitoes	animal[79]	new[79]	_	_
9-19	1476-1477	,	_	_	_	_
9-20	1478-1482	with	_	_	_	_
9-21	1483-1489	humans	animal	giv	coref	27-31
9-22	1490-1497	serving	_	_	_	_
9-23	1498-1500	as	_	_	_	_
9-24	1501-1511	amplifying	animal[81]	giv[81]	_	_
9-25	1512-1517	hosts	animal[81]	giv[81]	_	_
9-26	1518-1519	.	_	_	_	_

#Text=Unique among flaviviruses , ZIKV can persist in immune-privileged sites like the testis and be sexually transmitted .
10-1	1520-1526	Unique	_	_	_	_
10-2	1527-1532	among	_	_	_	_
10-3	1533-1545	flaviviruses	plant	giv	coref	11-4[86_0]
10-4	1546-1547	,	_	_	_	_
10-5	1548-1552	ZIKV	abstract	giv	coref	11-27[92_0]
10-6	1553-1556	can	_	_	_	_
10-7	1557-1564	persist	_	_	_	_
10-8	1565-1567	in	_	_	_	_
10-9	1568-1585	immune-privileged	place[84]	new[84]	_	_
10-10	1586-1591	sites	place[84]	new[84]	_	_
10-11	1592-1596	like	place[84]	new[84]	_	_
10-12	1597-1600	the	place[84]|object[85]	new[84]|new[85]	_	_
10-13	1601-1607	testis	place[84]|object[85]	new[84]|new[85]	_	_
10-14	1608-1611	and	_	_	_	_
10-15	1612-1614	be	_	_	_	_
10-16	1615-1623	sexually	_	_	_	_
10-17	1624-1635	transmitted	_	_	_	_
10-18	1636-1637	.	_	_	_	_

#Text=In addition to these well-known neurotropic flaviviruses , there has been an increasing number of reported cases of neurological complications caused by viruses , such as dengue virus ( DENV ) and yellow fever virus ( YFV ) , which usually are associated with hemorrhagic disease .
11-1	1638-1640	In	_	_	_	_
11-2	1641-1649	addition	_	_	_	_
11-3	1650-1652	to	_	_	_	_
11-4	1653-1658	these	plant[86]	giv[86]	coref	22-3[230_86]
11-5	1659-1669	well-known	plant[86]	giv[86]	_	_
11-6	1670-1681	neurotropic	plant[86]	giv[86]	_	_
11-7	1682-1694	flaviviruses	plant[86]	giv[86]	_	_
11-8	1695-1696	,	_	_	_	_
11-9	1697-1702	there	_	_	_	_
11-10	1703-1706	has	_	_	_	_
11-11	1707-1711	been	_	_	_	_
11-12	1712-1714	an	abstract[87]	new[87]	_	_
11-13	1715-1725	increasing	abstract[87]	new[87]	_	_
11-14	1726-1732	number	abstract[87]	new[87]	_	_
11-15	1733-1735	of	abstract[87]	new[87]	_	_
11-16	1736-1744	reported	abstract[87]|event[88]	new[87]|new[88]	_	_
11-17	1745-1750	cases	abstract[87]|event[88]	new[87]|new[88]	_	_
11-18	1751-1753	of	abstract[87]|event[88]	new[87]|new[88]	_	_
11-19	1754-1766	neurological	abstract[87]|event[88]|abstract[89]	new[87]|new[88]|giv[89]	_	_
11-20	1767-1780	complications	abstract[87]|event[88]|abstract[89]	new[87]|new[88]|giv[89]	_	_
11-21	1781-1787	caused	abstract[87]|event[88]|abstract[89]	new[87]|new[88]|giv[89]	_	_
11-22	1788-1790	by	abstract[87]|event[88]|abstract[89]	new[87]|new[88]|giv[89]	_	_
11-23	1791-1798	viruses	abstract[87]|event[88]|abstract[89]|animal[90]	new[87]|new[88]|giv[89]|new[90]	coref	21-7[216_90]
11-24	1799-1800	,	abstract[87]|event[88]|abstract[89]|animal[90]	new[87]|new[88]|giv[89]|new[90]	_	_
11-25	1801-1805	such	abstract[87]|event[88]|abstract[89]|animal[90]	new[87]|new[88]|giv[89]|new[90]	_	_
11-26	1806-1808	as	abstract[87]|event[88]|abstract[89]|animal[90]	new[87]|new[88]|giv[89]|new[90]	_	_
11-27	1809-1815	dengue	abstract[87]|event[88]|abstract[89]|animal[90]|object|abstract[92]	new[87]|new[88]|giv[89]|new[90]|new|giv[92]	appos	11-30[0_92]
11-28	1816-1821	virus	abstract[87]|event[88]|abstract[89]|animal[90]|abstract[92]	new[87]|new[88]|giv[89]|new[90]|giv[92]	_	_
11-29	1822-1823	(	_	_	_	_
11-30	1824-1828	DENV	abstract	giv	coref	11-33[95_0]
11-31	1829-1830	)	_	_	_	_
11-32	1831-1834	and	_	_	_	_
11-33	1835-1841	yellow	abstract[94]|abstract[95]	giv[94]|giv[95]	appos	11-37[0_95]
11-34	1842-1847	fever	abstract[94]|abstract[95]	giv[94]|giv[95]	_	_
11-35	1848-1853	virus	abstract[95]	giv[95]	_	_
11-36	1854-1855	(	_	_	_	_
11-37	1856-1859	YFV	abstract	giv	coref	13-12
11-38	1860-1861	)	_	_	_	_
11-39	1862-1863	,	_	_	_	_
11-40	1864-1869	which	_	_	_	_
11-41	1870-1877	usually	_	_	_	_
11-42	1878-1881	are	_	_	_	_
11-43	1882-1892	associated	_	_	_	_
11-44	1893-1897	with	_	_	_	_
11-45	1898-1909	hemorrhagic	abstract[97]	giv[97]	coref	27-28[0_97]
11-46	1910-1917	disease	abstract[97]	giv[97]	_	_
11-47	1918-1919	.	_	_	_	_

#Text=One of the central questions in the search for therapeutic targets for the treatment of flaviviral neurological syndromes is whether these diseases are induced by virus-mediated cytolysis , immune-pathological responses to infection , or a combination of both .
12-1	1920-1923	One	object[98]	new[98]	_	_
12-2	1924-1926	of	object[98]	new[98]	_	_
12-3	1927-1930	the	object[98]|abstract[99]	new[98]|new[99]	_	_
12-4	1931-1938	central	object[98]|abstract[99]	new[98]|new[99]	_	_
12-5	1939-1948	questions	object[98]|abstract[99]	new[98]|new[99]	_	_
12-6	1949-1951	in	object[98]|abstract[99]	new[98]|new[99]	_	_
12-7	1952-1955	the	object[98]|abstract[99]|event[100]	new[98]|new[99]|new[100]	_	_
12-8	1956-1962	search	object[98]|abstract[99]|event[100]	new[98]|new[99]|new[100]	_	_
12-9	1963-1966	for	object[98]|abstract[99]|event[100]	new[98]|new[99]|new[100]	_	_
12-10	1967-1978	therapeutic	object[98]|abstract[99]|event[100]|abstract[101]	new[98]|new[99]|new[100]|new[101]	coref	17-32[175_101]
12-11	1979-1986	targets	object[98]|abstract[99]|event[100]|abstract[101]	new[98]|new[99]|new[100]|new[101]	_	_
12-12	1987-1990	for	object[98]|abstract[99]|event[100]	new[98]|new[99]|new[100]	_	_
12-13	1991-1994	the	object[98]|abstract[99]|event[100]|abstract[102]	new[98]|new[99]|new[100]|new[102]	_	_
12-14	1995-2004	treatment	object[98]|abstract[99]|event[100]|abstract[102]	new[98]|new[99]|new[100]|new[102]	_	_
12-15	2005-2007	of	object[98]|abstract[99]|event[100]|abstract[102]	new[98]|new[99]|new[100]|new[102]	_	_
12-16	2008-2018	flaviviral	object[98]|abstract[99]|event[100]|abstract[102]|abstract[103]	new[98]|new[99]|new[100]|new[102]|giv[103]	_	_
12-17	2019-2031	neurological	object[98]|abstract[99]|event[100]|abstract[102]|abstract[103]	new[98]|new[99]|new[100]|new[102]|giv[103]	_	_
12-18	2032-2041	syndromes	object[98]|abstract[99]|event[100]|abstract[102]|abstract[103]	new[98]|new[99]|new[100]|new[102]|giv[103]	_	_
12-19	2042-2044	is	_	_	_	_
12-20	2045-2052	whether	_	_	_	_
12-21	2053-2058	these	abstract[104]	giv[104]	coref	13-45[123_104]
12-22	2059-2067	diseases	abstract[104]	giv[104]	_	_
12-23	2068-2071	are	_	_	_	_
12-24	2072-2079	induced	_	_	_	_
12-25	2080-2082	by	_	_	_	_
12-26	2083-2097	virus-mediated	abstract[105]	new[105]	_	_
12-27	2098-2107	cytolysis	abstract[105]	new[105]	_	_
12-28	2108-2109	,	_	_	_	_
12-29	2110-2129	immune-pathological	abstract[106]	new[106]	coref	13-38[122_106]
12-30	2130-2139	responses	abstract[106]	new[106]	_	_
12-31	2140-2142	to	abstract[106]	new[106]	_	_
12-32	2143-2152	infection	abstract[106]|event	new[106]|giv	coref	13-12[113_0]
12-33	2153-2154	,	_	_	_	_
12-34	2155-2157	or	_	_	_	_
12-35	2158-2159	a	abstract[108]	new[108]	_	_
12-36	2160-2171	combination	abstract[108]	new[108]	_	_
12-37	2172-2174	of	abstract[108]	new[108]	_	_
12-38	2175-2179	both	abstract[108]	new[108]	_	_
12-39	2180-2181	.	_	_	_	_

#Text=Animal models have permitted temporal analysis of the progressive dissemination of virus infection within the CNS and identification of cells targeted by viral infection , have revealed important details regarding host factors that restrict viral replication and the innate and adaptive immune responses to viral infections , and have been fundamental for vaccine development .
13-1	2182-2188	Animal	abstract[109]	new[109]	coref	16-19[151_109]
13-2	2189-2195	models	abstract[109]	new[109]	_	_
13-3	2196-2200	have	_	_	_	_
13-4	2201-2210	permitted	_	_	_	_
13-5	2211-2219	temporal	abstract[110]	new[110]	_	_
13-6	2220-2228	analysis	abstract[110]	new[110]	_	_
13-7	2229-2231	of	abstract[110]	new[110]	_	_
13-8	2232-2235	the	abstract[110]|abstract[111]	new[110]|new[111]	_	_
13-9	2236-2247	progressive	abstract[110]|abstract[111]	new[110]|new[111]	_	_
13-10	2248-2261	dissemination	abstract[110]|abstract[111]	new[110]|new[111]	_	_
13-11	2262-2264	of	abstract[110]|abstract[111]	new[110]|new[111]	_	_
13-12	2265-2270	virus	abstract[110]|abstract[111]|abstract|event[113]	new[110]|new[111]|giv|giv[113]	coref|coref	13-23[117_113]|17-17
13-13	2271-2280	infection	abstract[110]|abstract[111]|event[113]	new[110]|new[111]|giv[113]	_	_
13-14	2281-2287	within	abstract[110]|abstract[111]|event[113]	new[110]|new[111]|giv[113]	_	_
13-15	2288-2291	the	abstract[110]|abstract[111]|event[113]|abstract[114]	new[110]|new[111]|giv[113]|new[114]	_	_
13-16	2292-2295	CNS	abstract[110]|abstract[111]|event[113]|abstract[114]	new[110]|new[111]|giv[113]|new[114]	_	_
13-17	2296-2299	and	abstract[110]	new[110]	_	_
13-18	2300-2314	identification	abstract[110]|abstract[115]	new[110]|new[115]	_	_
13-19	2315-2317	of	abstract[110]|abstract[115]	new[110]|new[115]	_	_
13-20	2318-2323	cells	abstract[110]|abstract[115]|place[116]	new[110]|new[115]|new[116]	coref	14-8[131_116]
13-21	2324-2332	targeted	abstract[110]|abstract[115]|place[116]	new[110]|new[115]|new[116]	_	_
13-22	2333-2335	by	abstract[110]|abstract[115]|place[116]	new[110]|new[115]|new[116]	_	_
13-23	2336-2341	viral	abstract[110]|abstract[115]|place[116]|event[117]	new[110]|new[115]|new[116]|giv[117]	coref	17-17[172_117]
13-24	2342-2351	infection	abstract[110]|abstract[115]|place[116]|event[117]	new[110]|new[115]|new[116]|giv[117]	_	_
13-25	2352-2353	,	_	_	_	_
13-26	2354-2358	have	_	_	_	_
13-27	2359-2367	revealed	_	_	_	_
13-28	2368-2377	important	abstract[118]	new[118]	_	_
13-29	2378-2385	details	abstract[118]	new[118]	_	_
13-30	2386-2395	regarding	abstract[118]	new[118]	_	_
13-31	2396-2400	host	abstract[118]|person|abstract[120]	new[118]|new|new[120]	coref	16-45[157_0]
13-32	2401-2408	factors	abstract[118]|abstract[120]	new[118]|new[120]	_	_
13-33	2409-2413	that	abstract[118]|abstract[120]	new[118]|new[120]	_	_
13-34	2414-2422	restrict	abstract[118]|abstract[120]	new[118]|new[120]	_	_
13-35	2423-2428	viral	abstract[118]|abstract[120]|abstract[121]	new[118]|new[120]|new[121]	coref	23-13[0_121]
13-36	2429-2440	replication	abstract[118]|abstract[120]|abstract[121]	new[118]|new[120]|new[121]	_	_
13-37	2441-2444	and	abstract[118]|abstract[120]	new[118]|new[120]	_	_
13-38	2445-2448	the	abstract[118]|abstract[120]|abstract[122]	new[118]|new[120]|giv[122]	coref	23-45[258_122]
13-39	2449-2455	innate	abstract[118]|abstract[120]|abstract[122]	new[118]|new[120]|giv[122]	_	_
13-40	2456-2459	and	abstract[118]|abstract[120]|abstract[122]	new[118]|new[120]|giv[122]	_	_
13-41	2460-2468	adaptive	abstract[118]|abstract[120]|abstract[122]	new[118]|new[120]|giv[122]	_	_
13-42	2469-2475	immune	abstract[118]|abstract[120]|abstract[122]	new[118]|new[120]|giv[122]	_	_
13-43	2476-2485	responses	abstract[118]|abstract[120]|abstract[122]	new[118]|new[120]|giv[122]	_	_
13-44	2486-2488	to	abstract[118]|abstract[120]|abstract[122]	new[118]|new[120]|giv[122]	_	_
13-45	2489-2494	viral	abstract[118]|abstract[120]|abstract[122]|abstract[123]	new[118]|new[120]|giv[122]|giv[123]	coref	14-23[135_123]
13-46	2495-2505	infections	abstract[118]|abstract[120]|abstract[122]|abstract[123]	new[118]|new[120]|giv[122]|giv[123]	_	_
13-47	2506-2507	,	_	_	_	_
13-48	2508-2511	and	_	_	_	_
13-49	2512-2516	have	_	_	_	_
13-50	2517-2521	been	_	_	_	_
13-51	2522-2533	fundamental	_	_	_	_
13-52	2534-2537	for	_	_	_	_
13-53	2538-2545	vaccine	substance|abstract[125]	new|new[125]	coref	16-59[162_125]
13-54	2546-2557	development	abstract[125]	new[125]	_	_
13-55	2558-2559	.	_	_	_	_

#Text=Breakthroughs on cell reprogramming and generation of human induced pluripotent stem cells ( hiPSCs ) have revolutionized approaches to the study of human diseases .
14-1	2560-2573	Breakthroughs	event[126]	new[126]	_	_
14-2	2574-2576	on	event[126]	new[126]	_	_
14-3	2577-2581	cell	event[126]|place|event[128]	new[126]|new|new[128]	coref	18-29
14-4	2582-2595	reprogramming	event[126]|event[128]	new[126]|new[128]	_	_
14-5	2596-2599	and	event[126]	new[126]	_	_
14-6	2600-2610	generation	event[126]|abstract[129]	new[126]|new[129]	_	_
14-7	2611-2613	of	event[126]|abstract[129]	new[126]|new[129]	_	_
14-8	2614-2619	human	event[126]|abstract[129]|place[131]	new[126]|new[129]|giv[131]	coref	15-6[137_131]
14-9	2620-2627	induced	event[126]|abstract[129]|place[131]	new[126]|new[129]|giv[131]	_	_
14-10	2628-2639	pluripotent	event[126]|abstract[129]|place[131]	new[126]|new[129]|giv[131]	_	_
14-11	2640-2644	stem	event[126]|abstract[129]|plant|place[131]	new[126]|new[129]|new|giv[131]	coref	15-29
14-12	2645-2650	cells	event[126]|abstract[129]|place[131]	new[126]|new[129]|giv[131]	_	_
14-13	2651-2652	(	_	_	_	_
14-14	2653-2659	hiPSCs	abstract	new	coref	16-3
14-15	2660-2661	)	_	_	_	_
14-16	2662-2666	have	_	_	_	_
14-17	2667-2681	revolutionized	_	_	_	_
14-18	2682-2692	approaches	abstract[133]	new[133]	_	_
14-19	2693-2695	to	abstract[133]	new[133]	_	_
14-20	2696-2699	the	abstract[133]|abstract[134]	new[133]|new[134]	coref	23-2[240_134]
14-21	2700-2705	study	abstract[133]|abstract[134]	new[133]|new[134]	_	_
14-22	2706-2708	of	abstract[133]|abstract[134]	new[133]|new[134]	_	_
14-23	2709-2714	human	abstract[133]|abstract[134]|abstract[135]	new[133]|new[134]|giv[135]	coref	16-38[154_135]
14-24	2715-2723	diseases	abstract[133]|abstract[134]|abstract[135]	new[133]|new[134]|giv[135]	_	_
14-25	2724-2725	.	_	_	_	_

#Text=iPSCs are generated directly from adult differentiated cells that are reprogrammed back into an embryonic-like pluripotent state by introducing genes important for maintaining the essential properties of embryonic stem cells .
15-1	2726-2731	iPSCs	abstract	new	_	_
15-2	2732-2735	are	_	_	_	_
15-3	2736-2745	generated	_	_	_	_
15-4	2746-2754	directly	_	_	_	_
15-5	2755-2759	from	_	_	_	_
15-6	2760-2765	adult	place[137]	giv[137]	coref	15-28[142_137]
15-7	2766-2780	differentiated	place[137]	giv[137]	_	_
15-8	2781-2786	cells	place[137]	giv[137]	_	_
15-9	2787-2791	that	place[137]	giv[137]	_	_
15-10	2792-2795	are	place[137]	giv[137]	_	_
15-11	2796-2808	reprogrammed	place[137]	giv[137]	_	_
15-12	2809-2813	back	place[137]	giv[137]	_	_
15-13	2814-2818	into	place[137]	giv[137]	_	_
15-14	2819-2821	an	place[137]|abstract[138]	giv[137]|new[138]	_	_
15-15	2822-2836	embryonic-like	place[137]|abstract[138]	giv[137]|new[138]	_	_
15-16	2837-2848	pluripotent	place[137]|abstract[138]	giv[137]|new[138]	_	_
15-17	2849-2854	state	place[137]|abstract[138]	giv[137]|new[138]	_	_
15-18	2855-2857	by	_	_	_	_
15-19	2858-2869	introducing	_	_	_	_
15-20	2870-2875	genes	abstract[139]	new[139]	coref	21-39[223_139]
15-21	2876-2885	important	abstract[139]	new[139]	_	_
15-22	2886-2889	for	_	_	_	_
15-23	2890-2901	maintaining	_	_	_	_
15-24	2902-2905	the	abstract[140]	new[140]	_	_
15-25	2906-2915	essential	abstract[140]	new[140]	_	_
15-26	2916-2926	properties	abstract[140]	new[140]	_	_
15-27	2927-2929	of	abstract[140]	new[140]	_	_
15-28	2930-2939	embryonic	abstract[140]|place[142]	new[140]|giv[142]	ana	16-5[0_142]
15-29	2940-2944	stem	abstract[140]|plant|place[142]	new[140]|giv|giv[142]	coref	22-16
15-30	2945-2950	cells	abstract[140]|place[142]	new[140]|giv[142]	_	_
15-31	2951-2952	.	_	_	_	_

#Text=Generation of hiPSCs and their differentiation into a variety of cells and organoids have allow to set up versatile , non-invasive , ethically sustainable , cruelty-free , and patient-specific models for the investigation of the mechanisms of human diseases , including viral infections and host – pathogen interactions , for the discovery of new drugs , and for the development of personalized therapies .
16-1	2953-2963	Generation	abstract[143]	new[143]	_	_
16-2	2964-2966	of	abstract[143]	new[143]	_	_
16-3	2967-2973	hiPSCs	abstract[143]|abstract	new[143]|giv	coref	18-4
16-4	2974-2977	and	_	_	_	_
16-5	2978-2983	their	place|abstract[146]	giv|new[146]	coref|coref	16-11|18-29[188_146]
16-6	2984-2999	differentiation	abstract[146]	new[146]	_	_
16-7	3000-3004	into	abstract[146]	new[146]	_	_
16-8	3005-3006	a	abstract[146]|abstract[147]	new[146]|new[147]	_	_
16-9	3007-3014	variety	abstract[146]|abstract[147]	new[146]|new[147]	_	_
16-10	3015-3017	of	abstract[146]|abstract[147]	new[146]|new[147]	_	_
16-11	3018-3023	cells	abstract[146]|abstract[147]|place|place[149]	new[146]|new[147]|giv|giv[149]	coref|coref	16-11[149_0]|17-1[165_149]
16-12	3024-3027	and	abstract[146]|abstract[147]|place[149]	new[146]|new[147]|giv[149]	_	_
16-13	3028-3037	organoids	abstract[146]|abstract[147]|place[149]|abstract	new[146]|new[147]|giv[149]|new	coref	17-6[168_0]
16-14	3038-3042	have	_	_	_	_
16-15	3043-3048	allow	_	_	_	_
16-16	3049-3051	to	_	_	_	_
16-17	3052-3055	set	_	_	_	_
16-18	3056-3058	up	_	_	_	_
16-19	3059-3068	versatile	abstract[151]	giv[151]	coref	27-6[288_151]
16-20	3069-3070	,	abstract[151]	giv[151]	_	_
16-21	3071-3083	non-invasive	abstract[151]	giv[151]	_	_
16-22	3084-3085	,	abstract[151]	giv[151]	_	_
16-23	3086-3095	ethically	abstract[151]	giv[151]	_	_
16-24	3096-3107	sustainable	abstract[151]	giv[151]	_	_
16-25	3108-3109	,	abstract[151]	giv[151]	_	_
16-26	3110-3122	cruelty-free	abstract[151]	giv[151]	_	_
16-27	3123-3124	,	abstract[151]	giv[151]	_	_
16-28	3125-3128	and	abstract[151]	giv[151]	_	_
16-29	3129-3145	patient-specific	abstract[151]	giv[151]	_	_
16-30	3146-3152	models	abstract[151]	giv[151]	_	_
16-31	3153-3156	for	abstract[151]	giv[151]	_	_
16-32	3157-3160	the	abstract[151]|abstract[152]	giv[151]|new[152]	coref	20-8[210_152]
16-33	3161-3174	investigation	abstract[151]|abstract[152]	giv[151]|new[152]	_	_
16-34	3175-3177	of	abstract[151]|abstract[152]	giv[151]|new[152]	_	_
16-35	3178-3181	the	abstract[151]|abstract[152]|abstract[153]	giv[151]|new[152]|new[153]	_	_
16-36	3182-3192	mechanisms	abstract[151]|abstract[152]|abstract[153]	giv[151]|new[152]|new[153]	_	_
16-37	3193-3195	of	abstract[151]|abstract[152]|abstract[153]	giv[151]|new[152]|new[153]	_	_
16-38	3196-3201	human	abstract[151]|abstract[152]|abstract[153]|abstract[154]	giv[151]|new[152]|new[153]|giv[154]	coref	16-42[155_154]
16-39	3202-3210	diseases	abstract[151]|abstract[152]|abstract[153]|abstract[154]	giv[151]|new[152]|new[153]|giv[154]	_	_
16-40	3211-3212	,	abstract[151]|abstract[152]|abstract[153]	giv[151]|new[152]|new[153]	_	_
16-41	3213-3222	including	abstract[151]|abstract[152]|abstract[153]	giv[151]|new[152]|new[153]	_	_
16-42	3223-3228	viral	abstract[151]|abstract[152]|abstract[153]|abstract[155]|abstract[156]	giv[151]|new[152]|new[153]|giv[155]|giv[156]	coref	16-42[156_155]
16-43	3229-3239	infections	abstract[151]|abstract[152]|abstract[153]|abstract[155]|abstract[156]	giv[151]|new[152]|new[153]|giv[155]|giv[156]	_	_
16-44	3240-3243	and	abstract[151]|abstract[152]|abstract[153]|abstract[156]	giv[151]|new[152]|new[153]|giv[156]	_	_
16-45	3244-3248	host	abstract[151]|abstract[152]|abstract[153]|abstract[156]|person[157]|abstract[159]	giv[151]|new[152]|new[153]|giv[156]|giv[157]|new[159]	coref	23-45[0_157]
16-46	3249-3250	–	abstract[151]|abstract[152]|abstract[153]|abstract[156]|person[157]|abstract[159]	giv[151]|new[152]|new[153]|giv[156]|giv[157]|new[159]	_	_
16-47	3251-3259	pathogen	abstract[151]|abstract[152]|abstract[153]|abstract[156]|person[157]|substance|abstract[159]	giv[151]|new[152]|new[153]|giv[156]|giv[157]|new|new[159]	_	_
16-48	3260-3272	interactions	abstract[151]|abstract[152]|abstract[153]|abstract[156]|abstract[159]	giv[151]|new[152]|new[153]|giv[156]|new[159]	_	_
16-49	3273-3274	,	_	_	_	_
16-50	3275-3278	for	_	_	_	_
16-51	3279-3282	the	event[160]	new[160]	_	_
16-52	3283-3292	discovery	event[160]	new[160]	_	_
16-53	3293-3295	of	event[160]	new[160]	_	_
16-54	3296-3299	new	event[160]|substance[161]	new[160]|new[161]	_	_
16-55	3300-3305	drugs	event[160]|substance[161]	new[160]|new[161]	_	_
16-56	3306-3307	,	_	_	_	_
16-57	3308-3311	and	_	_	_	_
16-58	3312-3315	for	_	_	_	_
16-59	3316-3319	the	abstract[162]	giv[162]	coref	19-11[198_162]
16-60	3320-3331	development	abstract[162]	giv[162]	_	_
16-61	3332-3334	of	abstract[162]	giv[162]	_	_
16-62	3335-3347	personalized	abstract[162]|abstract[163]	giv[162]|new[163]	_	_
16-63	3348-3357	therapies	abstract[162]|abstract[163]	giv[162]|new[163]	_	_
16-64	3358-3359	.	_	_	_	_

#Text=Human iPSC-derived neural cells and brain organoids have been extensively used to investigate the mechanisms of ZIKV and other flavivirus infection and pathogenesis and have been used as platforms to discover therapeutic targets and to test antiviral compounds .
17-1	3360-3365	Human	place[165]|place[166]	giv[165]|giv[166]	coref|coref	17-1[166_165]|18-17[184_166]
17-2	3366-3378	iPSC-derived	abstract|place[165]|place[166]	new|giv[165]|giv[166]	coref	19-2
17-3	3379-3385	neural	place[165]|place[166]	giv[165]|giv[166]	_	_
17-4	3386-3391	cells	place[165]|place[166]	giv[165]|giv[166]	_	_
17-5	3392-3395	and	place[166]	giv[166]	_	_
17-6	3396-3401	brain	place[166]|object|abstract[168]	giv[166]|new|giv[168]	coref|coref	19-3|19-1[195_168]
17-7	3402-3411	organoids	place[166]|abstract[168]	giv[166]|giv[168]	_	_
17-8	3412-3416	have	_	_	_	_
17-9	3417-3421	been	_	_	_	_
17-10	3422-3433	extensively	_	_	_	_
17-11	3434-3438	used	_	_	_	_
17-12	3439-3441	to	_	_	_	_
17-13	3442-3453	investigate	_	_	_	_
17-14	3454-3457	the	abstract[169]	new[169]	coref	20-10[211_169]
17-15	3458-3468	mechanisms	abstract[169]	new[169]	_	_
17-16	3469-3471	of	abstract[169]	new[169]	_	_
17-17	3472-3476	ZIKV	abstract[169]|abstract|event[172]	new[169]|giv|giv[172]	coref|coref	18-15|18-26[186_172]
17-18	3477-3480	and	abstract[169]|event[172]	new[169]|giv[172]	_	_
17-19	3481-3486	other	abstract[169]|event[172]	new[169]|giv[172]	_	_
17-20	3487-3497	flavivirus	abstract[169]|plant|event[172]	new[169]|giv|giv[172]	_	_
17-21	3498-3507	infection	abstract[169]|event[172]	new[169]|giv[172]	_	_
17-22	3508-3511	and	abstract[169]	new[169]	_	_
17-23	3512-3524	pathogenesis	abstract[169]|abstract	new[169]|new	_	_
17-24	3525-3528	and	_	_	_	_
17-25	3529-3533	have	_	_	_	_
17-26	3534-3538	been	_	_	_	_
17-27	3539-3543	used	_	_	_	_
17-28	3544-3546	as	_	_	_	_
17-29	3547-3556	platforms	abstract	new	_	_
17-30	3557-3559	to	_	_	_	_
17-31	3560-3568	discover	_	_	_	_
17-32	3569-3580	therapeutic	abstract[175]	giv[175]	_	_
17-33	3581-3588	targets	abstract[175]	giv[175]	_	_
17-34	3589-3592	and	_	_	_	_
17-35	3593-3595	to	_	_	_	_
17-36	3596-3600	test	_	_	_	_
17-37	3601-3610	antiviral	substance[176]	new[176]	_	_
17-38	3611-3620	compounds	substance[176]	new[176]	_	_
17-39	3621-3622	.	_	_	_	_

#Text=Initial studies with hiPSCs studies were crucial to provide evidence of the tropism of ZIKV for human cortical neural progenitor cells and to demonstrate that ZIKV infection impairs cell differentiation and induces apoptosis , supporting the causative role of ZIKV in fetal microcephaly .
18-1	3623-3630	Initial	abstract[177]	new[177]	coref	18-4[179_177]
18-2	3631-3638	studies	abstract[177]	new[177]	_	_
18-3	3639-3643	with	abstract[177]	new[177]	_	_
18-4	3644-3650	hiPSCs	abstract[177]|abstract|abstract[179]	new[177]|giv|giv[179]	coref	23-25
18-5	3651-3658	studies	abstract[177]|abstract[179]	new[177]|giv[179]	_	_
18-6	3659-3663	were	_	_	_	_
18-7	3664-3671	crucial	_	_	_	_
18-8	3672-3674	to	_	_	_	_
18-9	3675-3682	provide	_	_	_	_
18-10	3683-3691	evidence	abstract[180]	new[180]	_	_
18-11	3692-3694	of	abstract[180]	new[180]	_	_
18-12	3695-3698	the	abstract[180]|abstract[181]	new[180]|new[181]	coref	22-12[232_181]
18-13	3699-3706	tropism	abstract[180]|abstract[181]	new[180]|new[181]	_	_
18-14	3707-3709	of	abstract[180]|abstract[181]	new[180]|new[181]	_	_
18-15	3710-3714	ZIKV	abstract[180]|abstract[181]|abstract	new[180]|new[181]|giv	coref	18-26
18-16	3715-3718	for	abstract[180]|abstract[181]	new[180]|new[181]	_	_
18-17	3719-3724	human	abstract[180]|abstract[181]|place[184]	new[180]|new[181]|giv[184]	coref	19-23[202_184]
18-18	3725-3733	cortical	abstract[180]|abstract[181]|place[184]	new[180]|new[181]|giv[184]	_	_
18-19	3734-3740	neural	abstract[180]|abstract[181]|place[184]	new[180]|new[181]|giv[184]	_	_
18-20	3741-3751	progenitor	abstract[180]|abstract[181]|object|place[184]	new[180]|new[181]|new|giv[184]	_	_
18-21	3752-3757	cells	abstract[180]|abstract[181]|place[184]	new[180]|new[181]|giv[184]	_	_
18-22	3758-3761	and	_	_	_	_
18-23	3762-3764	to	_	_	_	_
18-24	3765-3776	demonstrate	_	_	_	_
18-25	3777-3781	that	_	_	_	_
18-26	3782-3786	ZIKV	abstract|event[186]	giv|giv[186]	coref|coref	18-40|21-30[221_186]
18-27	3787-3796	infection	event[186]	giv[186]	_	_
18-28	3797-3804	impairs	_	_	_	_
18-29	3805-3809	cell	place|abstract[188]	giv|giv[188]	coref|coref	19-37|21-18[218_188]
18-30	3810-3825	differentiation	abstract[188]	giv[188]	_	_
18-31	3826-3829	and	_	_	_	_
18-32	3830-3837	induces	_	_	_	_
18-33	3838-3847	apoptosis	abstract	new	_	_
18-34	3848-3849	,	_	_	_	_
18-35	3850-3860	supporting	_	_	_	_
18-36	3861-3864	the	abstract[190]	new[190]	_	_
18-37	3865-3874	causative	abstract[190]	new[190]	_	_
18-38	3875-3879	role	abstract[190]	new[190]	_	_
18-39	3880-3882	of	abstract[190]	new[190]	_	_
18-40	3883-3887	ZIKV	abstract[190]|abstract	new[190]|giv	coref	19-20
18-41	3888-3890	in	abstract[190]	new[190]	_	_
18-42	3891-3896	fetal	abstract[190]|object[192]	new[190]|giv[192]	_	_
18-43	3897-3909	microcephaly	abstract[190]|object[192]	new[190]|giv[192]	_	_
18-44	3910-3911	.	_	_	_	_

#Text=Human iPSC-derived brain organoids , which are 3D structures mimicking endogenous human brain development and organization , showed that ZIKV preferentially infects radial glia cells as compared to intermediate progenitors or immature neurons , leading to cell death .
19-1	3912-3917	Human	abstract[195]	giv[195]	_	_
19-2	3918-3930	iPSC-derived	abstract|abstract[195]	giv|giv[195]	_	_
19-3	3931-3936	brain	object|abstract[195]	giv|giv[195]	coref	19-13
19-4	3937-3946	organoids	abstract[195]	giv[195]	_	_
19-5	3947-3948	,	abstract[195]	giv[195]	_	_
19-6	3949-3954	which	abstract[195]|abstract[196]	giv[195]|new[196]	_	_
19-7	3955-3958	are	abstract[195]|abstract[196]	giv[195]|new[196]	_	_
19-8	3959-3961	3D	abstract[195]|abstract[196]	giv[195]|new[196]	_	_
19-9	3962-3972	structures	abstract[195]|abstract[196]	giv[195]|new[196]	_	_
19-10	3973-3982	mimicking	abstract[195]|abstract[196]	giv[195]|new[196]	_	_
19-11	3983-3993	endogenous	abstract[195]|abstract[196]|abstract[198]	giv[195]|new[196]|giv[198]	_	_
19-12	3994-3999	human	abstract[195]|abstract[196]|abstract[198]	giv[195]|new[196]|giv[198]	_	_
19-13	4000-4005	brain	abstract[195]|abstract[196]|object|abstract[198]	giv[195]|new[196]|giv|giv[198]	_	_
19-14	4006-4017	development	abstract[195]|abstract[196]|abstract[198]	giv[195]|new[196]|giv[198]	_	_
19-15	4018-4021	and	abstract[195]|abstract[196]	giv[195]|new[196]	_	_
19-16	4022-4034	organization	abstract[195]|abstract[196]|abstract	giv[195]|new[196]|new	_	_
19-17	4035-4036	,	_	_	_	_
19-18	4037-4043	showed	_	_	_	_
19-19	4044-4048	that	_	_	_	_
19-20	4049-4053	ZIKV	abstract	giv	coref	20-13
19-21	4054-4068	preferentially	_	_	_	_
19-22	4069-4076	infects	_	_	_	_
19-23	4077-4083	radial	place[202]	giv[202]	coref	21-23[220_202]
19-24	4084-4088	glia	place|place[202]	new|giv[202]	_	_
19-25	4089-4094	cells	place[202]	giv[202]	_	_
19-26	4095-4097	as	_	_	_	_
19-27	4098-4106	compared	_	_	_	_
19-28	4107-4109	to	_	_	_	_
19-29	4110-4122	intermediate	animal[203]	new[203]	_	_
19-30	4123-4134	progenitors	animal[203]	new[203]	_	_
19-31	4135-4137	or	_	_	_	_
19-32	4138-4146	immature	animal[204]	new[204]	coref	23-35[254_204]
19-33	4147-4154	neurons	animal[204]	new[204]	_	_
19-34	4155-4156	,	_	_	_	_
19-35	4157-4164	leading	_	_	_	_
19-36	4165-4167	to	_	_	_	_
19-37	4168-4172	cell	place|event[206]	giv|new[206]	coref|coref	21-18|25-28[276_206]
19-38	4173-4178	death	event[206]	new[206]	_	_
19-39	4179-4180	.	_	_	_	_

#Text=Activation of TLR3-mediated innate immune response was one of the mechanisms involved ZIKV deleterious effects on neurogenesis .
20-1	4181-4191	Activation	abstract[207]	new[207]	_	_
20-2	4192-4194	of	abstract[207]	new[207]	_	_
20-3	4195-4208	TLR3-mediated	abstract[207]|abstract|abstract[209]	new[207]|new|new[209]	coref	26-22[283_209]
20-4	4209-4215	innate	abstract[207]|abstract[209]	new[207]|new[209]	_	_
20-5	4216-4222	immune	abstract[207]|abstract[209]	new[207]|new[209]	_	_
20-6	4223-4231	response	abstract[207]|abstract[209]	new[207]|new[209]	_	_
20-7	4232-4235	was	_	_	_	_
20-8	4236-4239	one	abstract[210]	giv[210]	_	_
20-9	4240-4242	of	abstract[210]	giv[210]	_	_
20-10	4243-4246	the	abstract[210]|abstract[211]	giv[210]|giv[211]	coref	27-14[290_211]
20-11	4247-4257	mechanisms	abstract[210]|abstract[211]	giv[210]|giv[211]	_	_
20-12	4258-4266	involved	abstract[210]|abstract[211]	giv[210]|giv[211]	_	_
20-13	4267-4271	ZIKV	abstract[210]|abstract[211]|abstract|abstract[213]	giv[210]|giv[211]|giv|new[213]	coref	22-6[231_0]
20-14	4272-4283	deleterious	abstract[210]|abstract[211]|abstract[213]	giv[210]|giv[211]|new[213]	_	_
20-15	4284-4291	effects	abstract[210]|abstract[211]|abstract[213]	giv[210]|giv[211]|new[213]	_	_
20-16	4292-4294	on	abstract[210]|abstract[211]|abstract[213]	giv[210]|giv[211]|new[213]	_	_
20-17	4295-4307	neurogenesis	abstract[210]|abstract[211]|abstract[213]|abstract	giv[210]|giv[211]|new[213]|new	_	_
20-18	4308-4309	.	_	_	_	_

#Text=In addition , the ability of viruses to infect and replicate was found to be dependent on cell differentiation status , since stem cells appear to be refractory to viral infection probably due to constitutive high-level expression of interferon-stimulated genes ( ISGs ) , while cell susceptibility to viral infection increases in differentiated cells .
21-1	4310-4312	In	_	_	_	_
21-2	4313-4321	addition	_	_	_	_
21-3	4322-4323	,	_	_	_	_
21-4	4324-4327	the	abstract[215]	new[215]	_	_
21-5	4328-4335	ability	abstract[215]	new[215]	_	_
21-6	4336-4338	of	abstract[215]	new[215]	_	_
21-7	4339-4346	viruses	abstract[215]|animal[216]	new[215]|giv[216]	_	_
21-8	4347-4349	to	abstract[215]|animal[216]	new[215]|giv[216]	_	_
21-9	4350-4356	infect	abstract[215]|animal[216]	new[215]|giv[216]	_	_
21-10	4357-4360	and	abstract[215]|animal[216]	new[215]|giv[216]	_	_
21-11	4361-4370	replicate	abstract[215]|animal[216]	new[215]|giv[216]	_	_
21-12	4371-4374	was	_	_	_	_
21-13	4375-4380	found	_	_	_	_
21-14	4381-4383	to	_	_	_	_
21-15	4384-4386	be	_	_	_	_
21-16	4387-4396	dependent	_	_	_	_
21-17	4397-4399	on	_	_	_	_
21-18	4400-4404	cell	place|abstract[218]|abstract[219]	giv|giv[218]|new[219]	coref|coref	21-46|24-16[265_218]
21-19	4405-4420	differentiation	abstract[218]|abstract[219]	giv[218]|new[219]	_	_
21-20	4421-4427	status	abstract[219]	new[219]	_	_
21-21	4428-4429	,	_	_	_	_
21-22	4430-4435	since	_	_	_	_
21-23	4436-4440	stem	place[220]	giv[220]	coref	21-53[228_220]
21-24	4441-4446	cells	place[220]	giv[220]	_	_
21-25	4447-4453	appear	_	_	_	_
21-26	4454-4456	to	_	_	_	_
21-27	4457-4459	be	_	_	_	_
21-28	4460-4470	refractory	_	_	_	_
21-29	4471-4473	to	_	_	_	_
21-30	4474-4479	viral	event[221]	giv[221]	coref	21-49[227_221]
21-31	4480-4489	infection	event[221]	giv[221]	_	_
21-32	4490-4498	probably	_	_	_	_
21-33	4499-4502	due	_	_	_	_
21-34	4503-4505	to	_	_	_	_
21-35	4506-4518	constitutive	abstract[222]	new[222]	coref	26-21[285_222]
21-36	4519-4529	high-level	abstract[222]	new[222]	_	_
21-37	4530-4540	expression	abstract[222]	new[222]	_	_
21-38	4541-4543	of	abstract[222]	new[222]	_	_
21-39	4544-4565	interferon-stimulated	abstract[222]|abstract[223]	new[222]|giv[223]	appos	21-42[0_223]
21-40	4566-4571	genes	abstract[222]|abstract[223]	new[222]|giv[223]	_	_
21-41	4572-4573	(	_	_	_	_
21-42	4574-4578	ISGs	abstract	giv	_	_
21-43	4579-4580	)	_	_	_	_
21-44	4581-4582	,	_	_	_	_
21-45	4583-4588	while	_	_	_	_
21-46	4589-4593	cell	place|abstract[226]	giv|new[226]	coref	24-17
21-47	4594-4608	susceptibility	abstract[226]	new[226]	_	_
21-48	4609-4611	to	abstract[226]	new[226]	_	_
21-49	4612-4617	viral	abstract[226]|event[227]	new[226]|giv[227]	coref	23-42[256_227]
21-50	4618-4627	infection	abstract[226]|event[227]	new[226]|giv[227]	_	_
21-51	4628-4637	increases	_	_	_	_
21-52	4638-4640	in	_	_	_	_
21-53	4641-4655	differentiated	place[228]	giv[228]	coref	22-15[234_228]
21-54	4656-4661	cells	place[228]	giv[228]	_	_
21-55	4662-4663	.	_	_	_	_

#Text=Comparisons with other flaviviruses — e.g. , DENV — showed that the tropism for neural stem cells was a distinguishing feature of ZIKV , but no extensive comparative analyses have been performed with typically neurotropic flaviviruses like WNV .
22-1	4664-4675	Comparisons	abstract[229]	new[229]	_	_
22-2	4676-4680	with	abstract[229]	new[229]	_	_
22-3	4681-4686	other	abstract[229]|plant[230]	new[229]|giv[230]	coref	22-34[238_230]
22-4	4687-4699	flaviviruses	abstract[229]|plant[230]	new[229]|giv[230]	_	_
22-5	4700-4701	—	_	_	_	_
22-6	4702-4706	e.g.	abstract[231]	giv[231]	coref	22-23[0_231]
22-7	4707-4708	,	abstract[231]	giv[231]	_	_
22-8	4709-4713	DENV	abstract[231]	giv[231]	_	_
22-9	4714-4715	—	_	_	_	_
22-10	4716-4722	showed	_	_	_	_
22-11	4723-4727	that	_	_	_	_
22-12	4728-4731	the	abstract[232]	giv[232]	coref	22-19[235_232]
22-13	4732-4739	tropism	abstract[232]	giv[232]	_	_
22-14	4740-4743	for	abstract[232]	giv[232]	_	_
22-15	4744-4750	neural	abstract[232]|place[234]	giv[232]|giv[234]	coref	23-27[252_234]
22-16	4751-4755	stem	abstract[232]|plant|place[234]	giv[232]|giv|giv[234]	_	_
22-17	4756-4761	cells	abstract[232]|place[234]	giv[232]|giv[234]	_	_
22-18	4762-4765	was	_	_	_	_
22-19	4766-4767	a	abstract[235]	giv[235]	coref	23-10[0_235]
22-20	4768-4782	distinguishing	abstract[235]	giv[235]	_	_
22-21	4783-4790	feature	abstract[235]	giv[235]	_	_
22-22	4791-4793	of	abstract[235]	giv[235]	_	_
22-23	4794-4798	ZIKV	abstract[235]|abstract	giv[235]|giv	coref	23-16
22-24	4799-4800	,	_	_	_	_
22-25	4801-4804	but	_	_	_	_
22-26	4805-4807	no	abstract[237]	new[237]	_	_
22-27	4808-4817	extensive	abstract[237]	new[237]	_	_
22-28	4818-4829	comparative	abstract[237]	new[237]	_	_
22-29	4830-4838	analyses	abstract[237]	new[237]	_	_
22-30	4839-4843	have	_	_	_	_
22-31	4844-4848	been	_	_	_	_
22-32	4849-4858	performed	_	_	_	_
22-33	4859-4863	with	_	_	_	_
22-34	4864-4873	typically	plant[238]	giv[238]	coref	26-6[278_238]
22-35	4874-4885	neurotropic	plant[238]	giv[238]	_	_
22-36	4886-4898	flaviviruses	plant[238]	giv[238]	_	_
22-37	4899-4903	like	plant[238]	giv[238]	_	_
22-38	4904-4907	WNV	plant[238]|abstract	giv[238]|giv	coref	23-21
22-39	4908-4909	.	_	_	_	_

#Text=In this study , we investigated the infectivity , tropism , and replication kinetics of ZIKV , in comparison with WNV and DENV in hiPSCs , hiPSCs-derived neural stem cells ( NSCs ) and undifferentiated neurons , and the effect of viral infection on host innate antiviral responses .
23-1	4910-4912	In	_	_	_	_
23-2	4913-4917	this	abstract[240]	giv[240]	coref	25-4[268_240]
23-3	4918-4923	study	abstract[240]	giv[240]	_	_
23-4	4924-4925	,	_	_	_	_
23-5	4926-4928	we	person	acc	ana	24-4
23-6	4929-4941	investigated	_	_	_	_
23-7	4942-4945	the	abstract[242]	new[242]	_	_
23-8	4946-4957	infectivity	abstract[242]	new[242]	_	_
23-9	4958-4959	,	_	_	_	_
23-10	4960-4967	tropism	abstract	giv	_	_
23-11	4968-4969	,	_	_	_	_
23-12	4970-4973	and	_	_	_	_
23-13	4974-4985	replication	abstract|abstract[245]	giv|new[245]	_	_
23-14	4986-4994	kinetics	abstract[245]	new[245]	_	_
23-15	4995-4997	of	abstract[245]	new[245]	_	_
23-16	4998-5002	ZIKV	abstract[245]|abstract	new[245]|giv	coref	23-23
23-17	5003-5004	,	_	_	_	_
23-18	5005-5007	in	_	_	_	_
23-19	5008-5018	comparison	abstract[247]	new[247]	_	_
23-20	5019-5023	with	abstract[247]	new[247]	_	_
23-21	5024-5027	WNV	abstract[247]|abstract	new[247]|giv	coref	25-17
23-22	5028-5031	and	abstract[247]	new[247]	_	_
23-23	5032-5036	DENV	abstract[247]|abstract	new[247]|giv	coref	24-9
23-24	5037-5039	in	abstract[247]	new[247]	_	_
23-25	5040-5046	hiPSCs	abstract[247]|abstract|abstract[251]	new[247]|giv|giv[251]	coref|coref	23-25[251_0]|24-6[0_251]
23-26	5047-5048	,	abstract[247]|abstract[251]	new[247]|giv[251]	_	_
23-27	5049-5063	hiPSCs-derived	abstract[247]|abstract[251]|place[252]	new[247]|giv[251]|giv[252]	coref	25-20[273_252]
23-28	5064-5070	neural	abstract[247]|abstract[251]|place[252]	new[247]|giv[251]|giv[252]	_	_
23-29	5071-5075	stem	abstract[247]|abstract[251]|place[252]	new[247]|giv[251]|giv[252]	_	_
23-30	5076-5081	cells	abstract[247]|abstract[251]|place[252]	new[247]|giv[251]|giv[252]	_	_
23-31	5082-5083	(	abstract[247]|abstract[251]	new[247]|giv[251]	_	_
23-32	5084-5088	NSCs	abstract[247]|abstract[251]|organization	new[247]|giv[251]|new	coref	25-12
23-33	5089-5090	)	abstract[247]|abstract[251]	new[247]|giv[251]	_	_
23-34	5091-5094	and	abstract[247]|abstract[251]	new[247]|giv[251]	_	_
23-35	5095-5111	undifferentiated	abstract[247]|abstract[251]|animal[254]	new[247]|giv[251]|giv[254]	coref	26-15[0_254]
23-36	5112-5119	neurons	abstract[247]|abstract[251]|animal[254]	new[247]|giv[251]|giv[254]	_	_
23-37	5120-5121	,	_	_	_	_
23-38	5122-5125	and	_	_	_	_
23-39	5126-5129	the	abstract[255]	new[255]	_	_
23-40	5130-5136	effect	abstract[255]	new[255]	_	_
23-41	5137-5139	of	abstract[255]	new[255]	_	_
23-42	5140-5145	viral	abstract[255]|event[256]	new[255]|giv[256]	coref	24-9[262_256]
23-43	5146-5155	infection	abstract[255]|event[256]	new[255]|giv[256]	_	_
23-44	5156-5158	on	abstract[255]	new[255]	_	_
23-45	5159-5163	host	abstract[255]|person|abstract[258]	new[255]|giv|giv[258]	_	_
23-46	5164-5170	innate	abstract[255]|abstract[258]	new[255]|giv[258]	_	_
23-47	5171-5180	antiviral	abstract[255]|abstract[258]	new[255]|giv[258]	_	_
23-48	5181-5190	responses	abstract[255]|abstract[258]	new[255]|giv[258]	_	_
23-49	5191-5192	.	_	_	_	_

#Text=In addition , we exploited hiPSCs to model ZIKV infection in the embryo and during stem cell differentiation towards the neuronal lineage .
24-1	5193-5195	In	_	_	_	_
24-2	5196-5204	addition	_	_	_	_
24-3	5205-5206	,	_	_	_	_
24-4	5207-5209	we	person	giv	_	_
24-5	5210-5219	exploited	_	_	_	_
24-6	5220-5226	hiPSCs	abstract	giv	_	_
24-7	5227-5229	to	_	_	_	_
24-8	5230-5235	model	_	_	_	_
24-9	5236-5240	ZIKV	abstract|event[262]	giv|giv[262]	coref|coref	25-10|27-7[0_262]
24-10	5241-5250	infection	event[262]	giv[262]	_	_
24-11	5251-5253	in	_	_	_	_
24-12	5254-5257	the	animal[263]	new[263]	_	_
24-13	5258-5264	embryo	animal[263]	new[263]	_	_
24-14	5265-5268	and	_	_	_	_
24-15	5269-5275	during	_	_	_	_
24-16	5276-5280	stem	abstract[265]	giv[265]	_	_
24-17	5281-5285	cell	place|abstract[265]	giv|giv[265]	coref	25-29
24-18	5286-5301	differentiation	abstract[265]	giv[265]	_	_
24-19	5302-5309	towards	abstract[265]	giv[265]	_	_
24-20	5310-5313	the	abstract[265]|abstract[266]	giv[265]|new[266]	_	_
24-21	5314-5322	neuronal	abstract[265]|abstract[266]	giv[265]|new[266]	_	_
24-22	5323-5330	lineage	abstract[265]|abstract[266]	giv[265]|new[266]	_	_
24-23	5331-5332	.	_	_	_	_

#Text=The results of this study confirmed the tropism of ZIKV for NSCs , but showed that WNV replicated in these cells with much higher efficiency , inducing massive cell death .
25-1	5333-5336	The	abstract[267]	new[267]	_	_
25-2	5337-5344	results	abstract[267]	new[267]	_	_
25-3	5345-5347	of	abstract[267]	new[267]	_	_
25-4	5348-5352	this	abstract[267]|abstract[268]	new[267]|giv[268]	_	_
25-5	5353-5358	study	abstract[267]|abstract[268]	new[267]|giv[268]	_	_
25-6	5359-5368	confirmed	_	_	_	_
25-7	5369-5372	the	abstract[269]	new[269]	coref	27-19[291_269]
25-8	5373-5380	tropism	abstract[269]	new[269]	_	_
25-9	5381-5383	of	abstract[269]	new[269]	_	_
25-10	5384-5388	ZIKV	abstract[269]|abstract	new[269]|giv	_	_
25-11	5389-5392	for	abstract[269]	new[269]	_	_
25-12	5393-5397	NSCs	abstract[269]|organization	new[269]|giv	_	_
25-13	5398-5399	,	_	_	_	_
25-14	5400-5403	but	_	_	_	_
25-15	5404-5410	showed	_	_	_	_
25-16	5411-5415	that	_	_	_	_
25-17	5416-5419	WNV	abstract	giv	_	_
25-18	5420-5430	replicated	_	_	_	_
25-19	5431-5433	in	_	_	_	_
25-20	5434-5439	these	place[273]	giv[273]	coref	26-11[279_273]
25-21	5440-5445	cells	place[273]	giv[273]	_	_
25-22	5446-5450	with	_	_	_	_
25-23	5451-5455	much	abstract[274]	new[274]	_	_
25-24	5456-5462	higher	abstract[274]	new[274]	_	_
25-25	5463-5473	efficiency	abstract[274]	new[274]	_	_
25-26	5474-5475	,	_	_	_	_
25-27	5476-5484	inducing	_	_	_	_
25-28	5485-5492	massive	event[276]	giv[276]	_	_
25-29	5493-5497	cell	place|event[276]	giv|giv[276]	_	_
25-30	5498-5503	death	event[276]	giv[276]	_	_
25-31	5504-5505	.	_	_	_	_

#Text=Although with lower efficiency , all flaviviruses could also infect pluripotent stem cells and neurons , inducing similar patterns of antiviral innate immune response gene expression .
26-1	5506-5514	Although	_	_	_	_
26-2	5515-5519	with	_	_	_	_
26-3	5520-5525	lower	abstract[277]	new[277]	_	_
26-4	5526-5536	efficiency	abstract[277]	new[277]	_	_
26-5	5537-5538	,	_	_	_	_
26-6	5539-5542	all	plant[278]	giv[278]	_	_
26-7	5543-5555	flaviviruses	plant[278]	giv[278]	_	_
26-8	5556-5561	could	_	_	_	_
26-9	5562-5566	also	_	_	_	_
26-10	5567-5573	infect	_	_	_	_
26-11	5574-5585	pluripotent	place[279]|place[280]	giv[279]|giv[280]	coref	26-11[280_279]
26-12	5586-5590	stem	place[279]|place[280]	giv[279]|giv[280]	_	_
26-13	5591-5596	cells	place[279]|place[280]	giv[279]|giv[280]	_	_
26-14	5597-5600	and	place[280]	giv[280]	_	_
26-15	5601-5608	neurons	place[280]|animal	giv[280]|giv	_	_
26-16	5609-5610	,	_	_	_	_
26-17	5611-5619	inducing	_	_	_	_
26-18	5620-5627	similar	abstract[282]	new[282]	_	_
26-19	5628-5636	patterns	abstract[282]	new[282]	_	_
26-20	5637-5639	of	abstract[282]	new[282]	_	_
26-21	5640-5649	antiviral	abstract[282]|abstract[285]	new[282]|giv[285]	_	_
26-22	5650-5656	innate	abstract[282]|abstract[283]|abstract[285]	new[282]|giv[283]|giv[285]	_	_
26-23	5657-5663	immune	abstract[282]|abstract[283]|abstract[285]	new[282]|giv[283]|giv[285]	_	_
26-24	5664-5672	response	abstract[282]|abstract[283]|abstract[285]	new[282]|giv[283]|giv[285]	_	_
26-25	5673-5677	gene	abstract[282]|abstract|abstract[285]	new[282]|new|giv[285]	_	_
26-26	5678-5688	expression	abstract[282]|abstract[285]	new[282]|giv[285]	_	_
26-27	5689-5690	.	_	_	_	_

#Text=While showing the usefulness of hiPSC-based infection models , these findings suggest that additional virus-specific mechanisms , beyond neural tropism , are responsible for the peculiarities of disease phenotype in humans .
27-1	5691-5696	While	_	_	_	_
27-2	5697-5704	showing	_	_	_	_
27-3	5705-5708	the	abstract[286]	new[286]	_	_
27-4	5709-5719	usefulness	abstract[286]	new[286]	_	_
27-5	5720-5722	of	abstract[286]	new[286]	_	_
27-6	5723-5734	hiPSC-based	abstract[286]|abstract[288]	new[286]|giv[288]	_	_
27-7	5735-5744	infection	abstract[286]|event|abstract[288]	new[286]|giv|giv[288]	_	_
27-8	5745-5751	models	abstract[286]|abstract[288]	new[286]|giv[288]	_	_
27-9	5752-5753	,	_	_	_	_
27-10	5754-5759	these	abstract[289]	new[289]	_	_
27-11	5760-5768	findings	abstract[289]	new[289]	_	_
27-12	5769-5776	suggest	_	_	_	_
27-13	5777-5781	that	_	_	_	_
27-14	5782-5792	additional	abstract[290]	giv[290]	_	_
27-15	5793-5807	virus-specific	abstract[290]	giv[290]	_	_
27-16	5808-5818	mechanisms	abstract[290]	giv[290]	_	_
27-17	5819-5820	,	abstract[290]	giv[290]	_	_
27-18	5821-5827	beyond	abstract[290]	giv[290]	_	_
27-19	5828-5834	neural	abstract[290]|abstract[291]	giv[290]|giv[291]	_	_
27-20	5835-5842	tropism	abstract[290]|abstract[291]	giv[290]|giv[291]	_	_
27-21	5843-5844	,	_	_	_	_
27-22	5845-5848	are	_	_	_	_
27-23	5849-5860	responsible	_	_	_	_
27-24	5861-5864	for	_	_	_	_
27-25	5865-5868	the	abstract[292]	new[292]	_	_
27-26	5869-5882	peculiarities	abstract[292]	new[292]	_	_
27-27	5883-5885	of	abstract[292]	new[292]	_	_
27-28	5886-5893	disease	abstract[292]|abstract|abstract[294]	new[292]|giv|new[294]	_	_
27-29	5894-5903	phenotype	abstract[292]|abstract[294]	new[292]|new[294]	_	_
27-30	5904-5906	in	abstract[292]|abstract[294]	new[292]|new[294]	_	_
27-31	5907-5913	humans	abstract[292]|abstract[294]|animal	new[292]|new[294]|giv	_	_
27-32	5914-5915	.	_	_	_	_
